Abstract:We demonstrate that bleomycin induces key features of experimental ALI including a profound increase in neutrophils in BALF (50–60%), pulmonary edema, and lung pathology on Day 3 after the challenge. Furthermore, we showed that key inflammatory markers including TGF‐β1, IL‐1β, TNF‐α, IL‐6, CINC‐1, TIMP‐1, and WISP‐1 were induced by studying their kinetic profile during the first 3 days after bleomycin injury. Our work adds to the knowledge of current ALI models and provides a set of experimental endpoints appropriate for efficacy testing of potential novel therapeutic treatments in ALI and for understanding mechanisms of action of therapeutics under investigation. The aim of this study was to describe and characterize the pathophysiological changes occurring during the early inflammatory phase (first 3 days) in the rat bleomycin model of lung injury preceding the development of fibrosis. Further, we wanted to understand the kinetics and factors contributing to bleomycin‐induced acute lung injury (ALI) and provide a robust, reliable and reproducible framework of features of ALI readouts to assess effects of therapeutics on bleomycin‐induced ALI in rats. We induced ALI in rats with intratracheal (i.t.) installation of bleomycin. The animals were sacrificed on predetermined time points, that is, Day 0, 1, 2, and 3 post the bleomycin challenge. We analyzed bronchoalveolar lavage fluid (BALF) and lung tissue to establish and assess relevant experimental features of ALI. We demonstrated that bleomycin induced key features of experimental ALI including a profound increase in neutrophils in BALF (50–60%), pulmonary edema, and lung pathology on Day 3 after challenge. Furthermore, we showed that TGF‐β1, IL‐1β, TNF‐α, IL‐6, CINC‐1, TIMP‐1, and WISP‐1 were induced by studying their kinetic profile during the first 3 days after bleomycin injury consistent with their known role ALI. We also confirmed that detectable fibrogenesis occurs at the earliest on Day 3 after injury based on collagen content, along with changes in the TGF‐β/Smad signaling pathway and increased expression of Galectin‐3, Vimentin, and Fibronectin in lung homogenate. Our report presents robust features and contributing mediators/factors to the pathology of bleomycin‐induced ALI in rats on Day 3. The kinetic data provide insights on the progression of ALI and a detailed understanding of early events before actual fibrosis development. This set of experimental endpoints is very appropriate and invaluable for efficacy testing of potential novel therapeutic treatments (single or combined) in ALI and understanding their mechanism of action.

Arginine concentration in arterial vs venous blood in a bleomycin-induced lung inflammation model in mice

Targeting Arginine in COVID-19-Induced Immunopathology and Vasculopathy

The Arginine Decarboxylase Pathways of Host and Pathogen Interact to Impact Inflammatory Pathways in the Lung.

Protective Effects of Functional Amino Acids on Apoptosis, Inflammatory Response, and Pulmonary Fibrosis in Lipopolysaccharide-Challenged Mice.

Evaluation of interleukin-1 and interleukin-6 receptor antagonists in a murine model of acute lung injury

Intravenous Arginine Administration Benefits CD4+ T-Cell Homeostasis and Attenuates Liver Inflammation in Mice with Polymicrobial Sepsis

N-Acetylglucosamine mitigates lung injury and pulmonary fibrosis induced by bleomycin

Arginine-mediated gut microbiome remodeling promotes host pulmonary immune defense against nontuberculous mycobacterial infection

Arginase Inhibition Prevents Inflammation and Remodeling in a Guinea Pig Model of Chronic Obstructive Pulmonary Disease

Protective Effect of Arbidol Against Pulmonary Fibrosis and Sepsis in Mice

Elevated levels of arginase activity are related to inflammation in patients with COPD exacerbation

Suppression of bleomycin-induced nitric oxide production in mice by taurine and niacin

Inhaled Argon Dilates Pulmonary Vasculature in Rat Isolated Lungs

Characterization of acute lung injury in the bleomycin rat model

Increased Oxidative Stress and Decreased Citrulline in Blood Associated with Severe Novel Coronavirus Pneumonia in Adult Patients

Alleviation of Hypoxic Pulmonary Vascular Structural Remodeling by L-arginine.

l-Arginine, as an essential amino acid, is a potential substitute for treating COPD via regulation of ROS/NLRP3/NF-κB signaling pathway

Polyamines as regulators of pulmonary inflammation

Therapeutic Modulation of Arginase with nor-NOHA Alters Immune Responses in Experimental Mouse Models of Pulmonary Tuberculosis including in the Setting of Human Immunodeficiency Virus (HIV) Co-Infection

L-Arginine, as an Important Metabolic Biomarker, Participates in the Pathological Process of Chronic Obstructive Pulmonary Disease

Progress in the protective effect and mechanism of arginine on lung injury